SCHEMBL7657748

SCHEMBL7657748

C[CH]CNC(=O)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
HTT P42858 1/20 0.56
TGM2 P21980 1/20 0.54
ALDH1A1 P00352 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
POLB P06746 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.52
MAPT P10636 1/20 0.51
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
CTSL P07711 1/20 0.50
CTSB P07858 1/20 0.50
CTSS P25774 1/20 0.50
CTSK P43235 1/20 0.50
PLAU P00749 1/20 0.49
KEAP1 Q14145 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL867055 0.85 LMNA (0.61) LMNASMN1; SMN2HTTTGM2ALDH1A1
SCHEMBL27647417 0.84 SMN1; SMN2 (0.56) LMNASMN1; SMN2HTTTGM2ALDH1A1
SCHEMBL15216787 0.84 SMN1; SMN2 (0.56) LMNASMN1; SMN2HTTTGM2ALDH1A1
SCHEMBL3826463 0.83 LMNA (0.59) LMNASMN1; SMN2HTTTGM2ALDH1A1
SCHEMBL195242 0.83 TGM2 (0.61) LMNASMN1; SMN2HTTTGM2ALDH1A1
SCHEMBL17244018 0.83 LMNA (0.59) LMNASMN1; SMN2HTTTGM2ALDH1A1
SCHEMBL4139120 0.83 HTT (0.54) LMNASMN1; SMN2HTTTGM2ALDH1A1
SCHEMBL4139126 0.83 HTT (0.54) LMNASMN1; SMN2HTTTGM2ALDH1A1
SCHEMBL8530400 0.82 LMNA (0.58) LMNASMN1; SMN2HTTTGM2ALDH1A1
SCHEMBL28661503 0.82 SMN1; SMN2 (0.58) LMNASMN1; SMN2HTTTGM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3050883-B1 PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVES AND INTERMEDIATES MEIJI SEIKA PHARMA CO LTD (JP) 2020-04-22 EP claimed
CN-104245671-B nitrogen-containing heterocyclic compound or salt thereof 富士胶片株式会社 2017-03-22 CN disclosed
US-9278944-B2 Nitrogen-containing saturated heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-03-08 US disclosed
US-20140011807-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2014-01-09 US disclosed
US-6495645-B1 INCORPORATING MANY SIDE FUNCTIONAL GROUPS WHILE MAINTAINING SENSITIVE TEMPERATURE RESPONSE Okano, Terou (JP) 2002-12-17 US disclosed
EP-1147076-A1 ACRYLAMIDE DERIVATIVES AND POLYMERS CONTAINING SAID DERIVATIVES Amersham Pharmacia Biotech K.K. (JP) 2001-10-24 EP disclosed
WO-2000043355-A1 ACRYLAMIDE DERIVATIVES AND POLYMERS CONTAINING SAID DERIVATIVES AMERSHAM PHARMACIA BIOTECH K.K. (JP) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140011807-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND REN, AGTR1, AGTR2 LMNA 2965/4885SMN1; SMN2 3926/4885HTT 2755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.